New Hormones for Advanced Breast Cancer

Beatson G.T. . On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases. Lancet. 1896; 2: 104–107.

Kimmick G. , Muss H.B. . Current status of endocrine therapy for metastatic breast cancer. Oncology. 1995; 9: 877–890.

A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia. J Clin Oncol. 1986; 4: 186–193.

Taylor SG 4th , Gelman R.S. , Falkson G. . Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med. 1986; 104: 455–461.

Iveson T.J. , A'Hern J. , Smith I.E. . Response to third-line endocrine treatment for advanced breast cancer. Eur J Cancer. 1993; 29A: 572–574.

Boccardo F. , Rubagotti A. , Perrotta A. . Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol. 1994; 5: 337–342.

Klijn J.G. , Seynaeve C. , Beex L. . Combined treatment with buserelin (LHRH-A) and tamoxifen (TAM) vs single treatment with each drug alone in premenopausal metastatic breast cancer: preliminary results of EORTC study 10881. Proc Annu Meet Am Soc Clin Oncol. 1996; 15: A132. Abstract.

Jonat W. , Kaufmann M. , Blamey R.W. . A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer. 1995; 31A: 137–142.

Howell A. , DeFriend D. , Robertson J. . Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet. 1995; 345: 29–30.

Buzdar A.U. , Plourde P.V. , Hortobagyi G.N. . Aromatase inhibitors in metastatic breast cancer. Semin Oncol. 1996; 23: 28–32.

Buzdar A.U. , Jones S.E. , Vogel C.L. . A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer. 1997; 79: 730–739.

Buzdar A.U. , Jonat W. , Howell A. . Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer. 1998; 83: 1142–1152.

Dombernowsky P. , Smith I. , Falkson G. . Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998; 16: 453–461.